Recombinant human Dnase I (rhDNase) in patients with lupus nephritis

Lupus

Volumn 8, Issue 1, 1999, Pages 68-76

  Davis Jr , J C ^a,f   Manzi, S ^c   Yarboro, C ^a   Rairie, J ^c   McInnes, I ^a   Averthelyi, D ^d   Sinicropi, D ^e   Hale, V G ^e   Balow, J ^b   Austin, H ^b   Boumpas, D T ^a   Klippel, J H ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^e GENENTECH INC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dornase alpha; Lupus; Treatment

Indexed keywords

AUTOANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DEOXYRIBONUCLEASE I; DORNASE ALFA; DOUBLE STRANDED DNA; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; NUCLEOPROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS; HELPER CELL; HUMAN; HYDROLYSIS; IMMUNE COMPLEX DEPOSITION; IMMUNOFLUORESCENCE; INTRAVENOUS DRUG ADMINISTRATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MULTICENTER STUDY; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; DEOXYRIBONUCLEASE I; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUPUS NEPHRITIS; MALE; RECOMBINANT PROTEINS;

EID: 0033043318     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120399678847380     Document Type: Article

References (37)

1. Swaak AJ, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986; 45: 359-366.
2. Swaak AJ, Aarden LA, Statius van Eps LW, Feltkamp TE. Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum 1979; 22: 226-235.
3. ter Borg EJ et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990; 33: 634-643.
4. Lloyd W, Schur PH. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore) 1981; 60: 208-217.
5. Winfield JB, Faiferman I, Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest 1977; 59: 90-96.
6. Kalunian KC et al. Idiotypic characteristics of immunoglobulins associated with systemic lupus erythematosus. Studies of antibodies deposited in glomeruli of humans. Arthritis Rheum 1989; 32: 513-522.
7. Koffler D, Schur PH, Kunkel HG. Immunological studies concerning the nephritis of systemic lupus erythematosus. J Exp Med 1967; 126: 607-624.
8. Andres GA et al. Localization of fluorescein-labeled antinucleoside antibodies in glomeruli of patients with active systemic lupus erythematosus nephritis. J Clin Invest 1970; 49: 2106-2118.
9. Lefkowith JB et al. Heterogeneity and clinical significance of glomerular-binding antibodies in systemic lupus erythematosus. J Clin Invest 1996; 98: 1373-1380.
10. Prince WS et al. Pharmacodynamics of recombinant human DNase I in serum. Clin Exp Immunol 1998; 113 (2): 289-296.
11. Lachmann PJ. Allergic reactions, connective tissue, and disease. Med Annu Rev 1967; 36-58.
12. Macanovic M et al. The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol 1996; 106: 243-252.
13. Klinman D, Elias K, Shak S, Verthelyi D. DNAse Treatment of DNA-Anti-DNA Immune Complexes in SLE. Arthritis Rheum 1996; 39: 1996.
14. Shak S et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87: 9188-9192.
15. Fuchs HJ et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642.
16. Shah PI et al. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. Eur Respir J 1995; 8: 954-958.
17. Wilmott RW et al. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. Am J Respir Crit Care Med 1996; 153: 1914-1917.
18. Johnson AJ, Goger PR, Tillett WS. The intravenous injection of bovine crystalline pancreatic desoxyribonuclease into patients. J Clin Invest 1954; 33: 1670-1686.
19. Ayvazian JH, Johnson AJ, Tillett WS. The use of parenterally administered pancreatic desoxyribonuclease as an adjunct in the treatment of pulmonary abscesses. Am Rev Tuberculosis Pulmonary Dis 1957; 76: 1-21.
20. Ayvazian A, Ayvazian L. The Effect of Crystalline Pancreatic Desoxyribonuclease in Patients with Gout. N Engl J Med 1960; 263: 999-1002.
21. Johnson AJ, Ayvazian JH, Tillett WS. Crystalline Pancreatic Desoxyribonuclease as Adjunct to Treatment of Pneumococcal Meningitis. N Engl J Med 1959; 260: 892-900.
22. Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
23. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1118.
24. Hagiwara E, Gourley MF, Lee S, Klinman DK. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 1996; 39: 379-385.
25. Klinman D et al. Quantitation of IgM- and IgG-secreting B cells in the peripheral blood of patients with systemic lupus erythematosus. Arthritis Rheum 1991; 34: 1404-1410.
26. Okamura M et al. Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. Ann Rheum Dis 1993; 52: 14-20.
27. Pankewycz OG, Migliorini P, Madaio MP. Polyreactive autoantibodies are nephritogenic in murine lupus nephritis. J Immunol 1987; 139: 3287-3294.
28. Chitrabamrung S, Rubin RL, Tan EM. Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus. Rheumatol Int 1981; 1: 55-60.
29. Macanovic M, Lachmann PJ. Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clin Exp Immunol 1997; 108: 220-226.
30. Budhai L, Oh K, Davidson A. An in vitro assay for detection of glomerular binding IgG autoantibodies in patients with systemic lupus erythematosus. J Clin Invest 1996; 98: 1585-1593.
31. Faaber P, Rijke TP, van de Putte LB, Capel PJ, Berden JH. Cross-reactivity of human and murine anti-DNA antibodies with heparan sulfate. The major glycosaminoglycan in glomerular basement membranes. J Clin Invest 1986; 77: 1824-1830.
32. Di Valerio R, Bernstein KA, Varghese E, Lefkowith JB. Murine lupus glomerulotropic monoclonal antibodies exhibit differing specificities but bind via a common mechanism. J Immunol 1995; 155: 2258-2268.
33. Sabbaga J, Line SR, Potocnjak P, Madaio MP. A murine nephritogenic monoclonal anti-DNA autoantibody binds directly to mouse laminin. the major non-collagenous protein component of the glomerular basement membrane. Eur J Immunol 1989; 19: 137-143.
34. Kramers C et al. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in viro. J Clin Invest 1994; 94: 568-577.
35. Elouaai F et al. Autoimmunity to histones, ubiquitin, and ubiquitinated histone H2A in NZB x NZW and MRL-lpr/lpr mice. Anti-histone antibodies are concentrated in glomerular eluates of lupus mice. Nephrol Dial Transplant 1994; 9: 362-366.
36. Chabre H et al. Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1995; 38: 1485-1491.
37. Tax WJ, Kramers C, van Bruggen MC, Berden JH. Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus [Editorial]. Kidney Int 1995; 48: 666-673.